Dr Markham gives an expert commentary at ASCO 2015 on immunotherapy data presented on the second day:
- A phase II trial that suggests that anti-CD38 antibody daratumumab is effective as a standalone therapy for heavily treated multiple myeloma.
- A phase III study finds that adding the new anti-CD20 monoclonal antibody obinutuzumab to standard bendamustine chemotherapy significantly delays progression of indolent non-Hodgkin lymphoma (NHL).
- A phase II study that has identified the first genomic marker mismatch repair (MMR) deficiency to predict response to the anti-PD-1 antibody pembrolizumab.
- A PERSIST-1 study of patients with myelofibrosis that suggest that pacritinib is significantly more effective than best available therapy (BAT), which includes a range of off-label treatments.
Read the news article for more.